What is it about?
This publication states for the first time the ability of oligopeptide-modified PBAE nanoparticles, encapsulating reporter mRNA to target antigen presenting cells (e.g. dendritic cells), if the terminal oligopeptides are carefully designed. It is the first proof-of-concept that these nanoparticles could be promising vaccines in a near future.
Featured Image
Why is it important?
The nanoparticles target antigen presenting cells by themselves. The synthesis of these nanotools is easy and cheap, becoming a promising nanomedicine available for large population groups.
Perspectives
I see this publication as the first step in the way to reach to mRNA vaccines for multiple purposes. It opens a new window of development.
Dr Cristina Fornaguera
Institut Químic de Sarrià - Ramon Llull University
Read the Original
This page is a summary of: mRNA Delivery System for Targeting Antigen-Presenting Cells In Vivo, Advanced Healthcare Materials, June 2018, Wiley,
DOI: 10.1002/adhm.201800335.
You can read the full text:
Contributors
The following have contributed to this page
